PFIZERMECTIN? Big Pharma Testing COVID Treatments That Work Like The Drug Smeared As ‘Horse Dewormer’

Written by K. Walker on September 29, 2021

Become a Clash Insider!

Big Tech is clamping down on conservative media big time. Don’t let Big Tech pre-chew your news. Sign up for our free email newsletter, and we’ll make sure to keep you in the loop.


Now that Big Pharma has made billions of dollars on vaccines that are waning in efficacy, they’re turning their attention to therapeutics.

It’s about time.

But then, it’s no surprise that they’ve waited so long. If a successful treatment for SARS-CoV-2 was available, that would negate the need for the “emergency use” of new vaccines that haven’t been tested for long-term effects. Governments would also be considered downright evil for mandating vaccines when treatment was available.

A cynical person might think that the muckety-mucks in the Pharmaceutical industry would be reticent to seek out such treatment — even if it could save lives — because it would interfere with their cash cow. But then, we all know that that’s ridiculous since Big Pharma has been committed to making life better for everyone. It’s not like they’ve been known to hide information — like, I don’t know, the addictiveness of pain killers. They’d never do something like that — there would be such a high cost if there was a problem with opioid addiction. It would be just crazy to believe that Big Pharma cares more about profits than people, right?

Interestingly, Pfizer, who bragged that their mRNA Coronavirus vaccine was 95% effective now requires a third dose 8 months in — but it’s probably more like 6 months according to an infectious disease expert quoted in a NY Times article that suggested that the booster protects for about 12 days — is now focused on testing a treatment for the Wuhan Virus using oral anti-virals.

What is very interesting about this Pfizer treatment is that it’s a protease inhibitor.

The cheap, no longer patented, Nobel Prize-winning “miracle drug” Ivermectin, which is an anti-parasitic drug that has been used in humans for decades has also been shown to be a protease inhibitor.

Still, the press called it a “horse dewormer” that the dumb “anti-vaxxers” — like Joe Rogan — were taking instead of just getting the jab.

Protease inhibitors are antiviral drugs that adhere to specific enzymes in the body — they don’t cure viral infections, but they can prevent a virus from replicating in the body by blocking the proteins that they need. They are used in flu medications like Tamiflu, but more commonly are used as a treatment for patients with Hepatitis-C, HIV, and AIDs.

Back in May, Pfizer CEO Albert Bourla said on CNBC that Pfizer’s drug, currently called PF-07321332, could be a “cure” for COVID.

JOE KERNEN: Albert, in a New York paper, it’s the Post, COVID cure may be ready this year from a Pfizer drug it’s a, it’s a, you know which one I’m talking about PF-07321332 is what it said but it prevents a replication of COVID in the nose and it could be an oral medication and they’re calling it a cure, could be ready next year. Is that headline accurate?

BOURLA: Well, it is accurate that we are working on the variant and we’re actually on two, one is injectable and the other one as you just said it is an oral. And particularly the attention is on the oral of the world and of us because provides several advantages and one of them is that you don’t need to go to the hospital to get the treatment of which is the case with all the injectables so far but you can get it home. That could be a game changer. The compound that we are talking about and you said very well the numbers, it is a protease inhibitor. The good thing is that this is also the first molecule that is coming from this type of class, this is good thing because you can combine it with other classes. Also, the mechanism of action, it is such that it’s not expected to be subject to mutations, particularly because it’s not acting on the spike, as we all know, all the mutations that we are hearing right now are seeing this in the proteins of the spike. This one doesn’t work there so that allows us to believe that will be way more effective against the multiple variants. So, all good news. We are now progressing the studies and we will have more news around summer.

Funny how all of a sudden, the Corporate Media was railing against ivermectin as a “horse dewormer” recently, isn’t it? It’s all happening just as the clinical trials are running for protease inhibitors to treat the coronavirus… what a coincidence!

People online started noticing that after all of the mocking of Ivermectin, Pfizer’s med looks kinda like… Ivermectin.

It’s unclear if Pfizer’s med will be a “cure” — after all, we were promised that the vaccines would bring us back to “normal life” everywhere and they didn’t. But, if what happened to Judith Smentkiewicz of Cheektowaga, New York is any indication, the copycat version of Ivermectin might save some lives.

MIRACLE DRUG: Hospital Refused To Give Dying 80 Yr. Old COVID Patient Trial Medication — State Judge’s Order Saved Her Life

But it’s not just Pfizer that’s in the running for an antiviral.

Merck, the drug company that produces Stromectol — the prescription version of Ivermectin — issued a statement in February 2021 stating that their drug should not be used for the treatment of the Wuhan Virus unless it is being used as part of a clinical trial.

In completely unrelated news, Merck inked a $1.2 billion deal with the U.S. in July to provide an antiviral therapy for the coronavirus.

Merck has struggled to develop therapeutics and vaccines to fight COVID-19. But the United States is betting that the pharmaceutical giant at last has a winner in its oral antiviral molnupiravir.

On Wednesday Merck revealed a deal to supply 1.7 million courses of the experimental treatment to the U.S. for approximately $1.2 billion. Molnupiravir has yet to be approved, but it’s shown promise for newly diagnosed, non-hospitalized COVID-19 patients.

The drug, developed in collaboration with Ridgeback Biotherapeutics, is in phase 3 testing. With positive results, Merck expects to apply for emergency authorization later this year.
Source: Fierce Pharma

Merck is no stranger to creating antivirals, it also produces an inexpensive protease inhibitor drug Indinavir that has been used since the mid-90s for treating HIV/AIDs.

What a strange and baffling coincidence!

The Long Island Press reports that the competition to find an effective SARS-CoV-2 treatment is (finally) heating up.

As Merck & Co and Pfizer Inc prepare to report clinical trial results for experimental Covid–19 antiviral pills, rivals are lining up with what they hope will prove to be more potent and convenient oral treatments of their own.

Enanta Pharmaceuticals, Pardes Biosciences, Japan’s Shionogi & Co. Ltd. and Novartis AG said they have designed antivirals that specifically target the coronavirus while aiming to avoid potential shortcomings such as the need for multiple pills per day or known safety issues…

…Pfizer and Merck, as well as partners Atea Pharmaceuticals and Roche AG have all said they could seek emergency approval for their Covid–19 antiviral pills this year.

Rivals are at least a year behind. Pardes began an early-stage trial last month, Shionogi plans to start large-scale clinical trials by year-end, Enanta aims to start human trials early next year and Novartis is still testing its pill in animals.

What kinds of oral antivirals are being used?

Why… protease inhibitors, of course! Also being tested are polymerase inhibitors like Remdesivir that was famously used by President Trump when he tested positive for the coronavirus.

Several classes of antiviral drugs are being explored. Polymerase inhibitors such as Atea’s drug – first developed for hepatitis C – aim to disrupt the ability of the coronavirus to make copies of itself. There are also protease inhibitors, like Pfizer’s pill, which are designed to block an enzyme the virus needs in order to multiply earlier in its lifecycle.

We are trying to halt the processes “that allow the virus to set up a replication factory,” said Uri Lopatin, CEO at Pardes, which is also developing a COVID–19 protease inhibitor.

Merck’s molnupiravir, developed with Ridgeback Biotherapeutics, was at one point envisioned as a flu drug and works by introducing errors into the genetic code of the virus.
Source: Long Island Press

Well, look at that! It looks like there are some treatment options coming down from on high.

Of course, some places that don’t have access to vaccines have been using what they had on hand with some pretty stunning success:

You Might Like
ClashDaily's Associate Editor since August 2016. Self-described political junkie, anti-Third Wave Feminist, and a nightmare to the 'intersectional' crowd. Mrs. Walker has taken a stand against 'white privilege' education in public schools. She's also an amateur Playwright, former Drama teacher, and staunch defender of the Oxford comma. Follow her humble musings on Twitter: @TheMrsKnowItAll